![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Antiviral Activity and Safety of INX-08189, a Nucleotide Polymerase Inhibitor, Following 7-Days of Oral Therapy in Naďve Genotype-1 HCV Patients
|
|
|
Reported by Jules Levin AASLD Nov 5-9 2011 San Francisco
M Rodriguez-Torres1, E Lawitz2, L Hazan3, A Barry4, E Wenzel4, J Alam5, G Henson4, J Patti4
1Fundación de Investigación, San Juan, PR; 2Alamo Medical Research, Ltd. San Antonio, TX; 3Axis Clinical Trials, Los Angeles, CA; 5Sanofi Aventis, Paris, France; 4Inhibitex, Inc., Alpharetta, GA
![AASLD1.gif](../images/110711/110711-6/AASLD1.gif)
![AASLD2.gif](../images/110711/110711-6/AASLD2.gif)
![AASLD3.gif](../images/110711/110711-6/AASLD3.gif)
![AASLD4.gif](../images/110711/110711-6/AASLD4.gif)
![AASLD5.gif](../images/110711/110711-6/AASLD5.gif)
![AASLD6.gif](../images/110711/110711-6/AASLD6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|